We read with great interest the article by Denkert et al. [1] about the prognostic role of Ki67 among breast cancer patients treated with neoadjuvant therapy. We think, however, that the different composition of population in clinical practice in comparison with population in the trial could be kept in mind.
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Among the 1475 cases of breast cancer diagnosed in [2004] [2005] in residents in the area of Firenze and Prato, collected by Tuscan Cancer Registry, and with Ki67 score available, we found a low Ki67 expression (≤15%) in more than half of the cases (58% of total); moreover, in this population-based database, the luminal A cases constituted 70% of the series [2] while, in the trial by Denkert [1], they were 53% of the total. Probably, in the population by trial, the low-risk breast cancer patients are underrepresented, and this feature can influence the results about the prognostic effect of Ki67 in this group.
We carried out an ROC curve to assess the best cutoff of Ki67 for predicting overall survival among the luminal A and B cases: a value of 15%, as proposed by Denkert et al. [1] , correctly classified only 55% of cases, with a sensitivity of 64% and specificity of 54%. The other Ki67 cutoff (35%) proposed by Denkert et al.
[1] correctly classified 83% of luminal cases: the specificity was 90.4% but the sensitivity, that is the ability to identify the patients with high risk to die, was low (20.1%).
We think that the prognostic role of Ki67 in a normal population remains unclear, even in luminal breast cancers. Therefore, further studies need to correctly evaluate the use of this marker in the clinical practice. There are some open technical questions to the registry data: were the Ki67 values determined by exact counting rather than estimation? How was standardization achieved? These technical issues are more difficult to control in a registry-based setting. Furthermore, slightly different values might be obtained in core biopsies and in large tumor sections due to intratumoral heterogeneity. It would be extremely interesting to perform the complete cut point analysis using the cutoff finder approach and the molecular subtype radar diagrams, as described in our paper, also in the registry population. Cutoff finder [3] is freely available on a webpage (http://molpath.charite.de/cutoff/). A direct comparison with the same approach would stimulate the discussion in this area.
Furthermore, it would be interesting to stratify the registry data according to the different treatment that was given to the patients. We have shown in Figure 4 of our paper that Ki67 is a negative prognostic factor for tumors with poor response to chemotherapy, while it is a positive prognostic factor for tumors with a pathological complete response, which demonstrates that the therapy approach will also change the results that we get out of the Ki67 analysis.
However, despite these open questions, the investigation by Caldarella et al. illustrates a very important issue: there is no 'normal population' in breast cancer, and it always depends on the viewpoint of the researcher. From an epidemiology point of view, a normal population is a registry-based population. However, for many of these patients, the determination of Ki67 might not be needed, because they are low risk anyway and would not require additional treatment. From the view of a clinical oncologist, a normal population is a population from a clinical trial with defined entry criteria and identical treatment. Even if we would define a cut point using a large registry cohort,
